AAPL   380.39 (-0.40%)
MSFT   205.62 (-0.70%)
AMZN   3,023.22 (-2.60%)
TSLA   1,492.05 (-0.33%)
F   6.34 (+4.28%)
BAC   23.92 (-1.12%)
AAPL   380.39 (-0.40%)
MSFT   205.62 (-0.70%)
AMZN   3,023.22 (-2.60%)
TSLA   1,492.05 (-0.33%)
F   6.34 (+4.28%)
BAC   23.92 (-1.12%)
AAPL   380.39 (-0.40%)
MSFT   205.62 (-0.70%)
AMZN   3,023.22 (-2.60%)
TSLA   1,492.05 (-0.33%)
F   6.34 (+4.28%)
BAC   23.92 (-1.12%)
AAPL   380.39 (-0.40%)
MSFT   205.62 (-0.70%)
AMZN   3,023.22 (-2.60%)
TSLA   1,492.05 (-0.33%)
F   6.34 (+4.28%)
BAC   23.92 (-1.12%)
Log in

NASDAQ:TTOOT2 Biosystems Stock Price, Forecast & News

$1.48
+0.15 (+11.28 %)
(As of 07/14/2020 01:14 PM ET)
Add
Compare
Today's Range
$1.36
Now: $1.48
$1.52
50-Day Range
$0.74
MA: $1.26
$1.67
52-Week Range
$0.24
Now: $1.48
$3.21
Volume466,916 shs
Average Volume16.57 million shs
Market Capitalization$176.92 million
P/E RatioN/A
Dividend YieldN/A
Beta1.13
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company also offers T2Dx, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood. In addition, it is developing Candida Auris, a multi-drug resistant pathogen; T2Bacteria, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; and T2Lyme for the detection of various strains of Lyme disease-causing bacteria. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease; and Allergan Sales, LLC to develop detection diagnostic test panel that adds one additional bacteria species to the existing T2Bacteria product candidate, as well as for testing drug resistance directly in whole blood. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.
Read More
T2 Biosystems logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.34 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TTOO
CUSIPN/A
Phone781-761-4646

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.34 million
Book Value($0.73) per share

Profitability

Net Income$-59,010,000.00
Net Margins-645.05%

Miscellaneous

Employees151
Market Cap$176.92 million
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive TTOO News and Ratings via Email

Sign-up to receive the latest news and ratings for TTOO and its competitors with MarketBeat's FREE daily newsletter.

T2 Biosystems (NASDAQ:TTOO) Frequently Asked Questions

How has T2 Biosystems' stock been impacted by COVID-19 (Coronavirus)?

T2 Biosystems' stock was trading at $0.4950 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TTOO stock has increased by 199.0% and is now trading at $1.48. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of T2 Biosystems?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for T2 Biosystems.

When is T2 Biosystems' next earnings date?

T2 Biosystems is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for T2 Biosystems.

How were T2 Biosystems' earnings last quarter?

T2 Biosystems Inc (NASDAQ:TTOO) issued its quarterly earnings results on Tuesday, May, 5th. The medical equipment provider reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.28) by $0.06. The medical equipment provider had revenue of $2.55 million for the quarter. View T2 Biosystems' earnings history.

What guidance has T2 Biosystems issued on next quarter's earnings?

T2 Biosystems issued an update on its second quarter 2020 After-Hours earnings guidance on Tuesday, June, 30th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.4-2.6 million, compared to the consensus revenue estimate of $2.44 million.

What price target have analysts set for TTOO?

6 analysts have issued 12-month price objectives for T2 Biosystems' shares. Their forecasts range from $0.40 to $6.00. On average, they expect T2 Biosystems' share price to reach $2.85 in the next twelve months. This suggests a possible upside of 92.6% from the stock's current price. View analysts' price targets for T2 Biosystems.

What are Wall Street analysts saying about T2 Biosystems stock?

Here are some recent quotes from research analysts about T2 Biosystems stock:
  • 1. According to Zacks Investment Research, "T2 Biosystems, Inc. is an in vitro diagnostics company. It has developed a technology platform that is designed to offer a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company uses its T2 Magnetic Resonance platform, or T2MR, that enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets. It operates primarily in the United States. T2 Biosystems, Inc. is headquartered in Lexington, Massachusetts. " (7/7/2020)
  • 2. HC Wainwright analysts commented, "We do not currently have a price target on TTOO shares. Risks include, but are not limited to: (1) failure of to achieve commercial success due to market size, penetration rate, and/or competition; (2) failure to secure regulatory approval for T2Lyme; and (3) potential dilution risk." (8/7/2019)

Has T2 Biosystems been receiving favorable news coverage?

News articles about TTOO stock have trended somewhat positive this week, InfoTrie reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. T2 Biosystems earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned news articles about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about T2 Biosystems.

Who are some of T2 Biosystems' key competitors?

What other stocks do shareholders of T2 Biosystems own?

Who are T2 Biosystems' key executives?

T2 Biosystems' management team includes the following people:
  • Prof. Michael J. Cima, Co-Founder & Independent Director (Age 60, Pay $62.5k)
  • Mr. Alec Barclay, Sr. VP of Operations (Age 39, Pay $477.4k)
  • Dr. Thomas J. Lowery Jr., Chief Scientific Officer (Age 41, Pay $473.93k)
  • Mr. John J. Sperzel III, Pres, CEO & Director (Age 56)
  • Dr. Tyler E. Jacks, Co-Founder (Age 59)

What is T2 Biosystems' stock symbol?

T2 Biosystems trades on the NASDAQ under the ticker symbol "TTOO."

How do I buy shares of T2 Biosystems?

Shares of TTOO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is T2 Biosystems' stock price today?

One share of TTOO stock can currently be purchased for approximately $1.48.

How big of a company is T2 Biosystems?

T2 Biosystems has a market capitalization of $176.92 million and generates $8.34 million in revenue each year. The medical equipment provider earns $-59,010,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis. T2 Biosystems employs 151 workers across the globe.

What is T2 Biosystems' official website?

The official website for T2 Biosystems is www.t2biosystems.com.

How can I contact T2 Biosystems?

T2 Biosystems' mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The medical equipment provider can be reached via phone at 781-761-4646 or via email at [email protected]

This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.